Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Defibrotide for prevention of acute graft-versus-host disease after allogeneic HSCT
2017-003309-16Phase 2Completed
- Sponsor
- Jazz Pharmaceuticals plc
- Start
- Nov 2017
- Modality
- Vaccine mRNA → mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in Acute Graft-Versus-Host Disease (aGvHD) comparing Defibrotide + standard-of-care immunoprophylaxis with Standard-of-care immunoprophylaxis alone (2 arms). Primary endpoint: Cumulative incidence of Grade B-D acute graft-versus-host disease by Day +100 post-HSCT. Started Nov 2017; status: completed.
02
Drugs
defibrotide
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on 2017-003309-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003309-16.